Anja Diem

Dr. Anja Diem

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
VWVerena Wally
Verena Wally
SKSophie Kitzmueller
Sophie Kitzmueller
FLFlorian Lagler
Florian Lagler
AMAngelika Moder
Angelika Moder
Wolfgang HitzlWolfgang Hitzl
Wolfgang Hitzl
JBJohann W Bauer
Johann W Bauer
Blistering in epidermolysis bullosa simplex type Dowling-Meara (EBS-DM) is associated with an inflammatory phenotype, which can be disrupted by diacerein in vitro. In this pilot study we hypothesized, that a topical formulation of diacerein 1% reduces blistering. Five patients initially applied diacerein underneath both armpits. Then, each participant received 1% diacerein-cream for one armpit, and placebo for the other (randomized withdrawal). The number of blisters was reduced significantly (left: -78%; right: -66% of baseline) within two weeks and remained significantly below the initial level even during withdrawal in four patients. These findings point to a relevant effect of diacerein and provide important information for a confirmative study.

25 April 2006 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
KSKlaus Seppi
Klaus Seppi
BHBirgit Högl
Birgit Högl
ADAnja Diem
Anja Diem
CPCecilia Peralta
Cecilia Peralta
GWGregor K. Wenning
Gregor K. Wenning
WPWerner Poewe
Werner Poewe

1 December 2016 in Wiener klinische Wochenschrift
Verified
Journal Article
Open access
PDF file
MLMartin Laimer
Martin Laimer
GPGabriela Pohla-Gubo
Gabriela Pohla-Gubo
ADAnja Diem
Anja Diem
CPChristine Prodinger
Christine Prodinger
JBJohann W Bauer
Johann W Bauer
HHHelmut Hintner
Helmut Hintner
Accurately addressing the diverse and complex issues of rare diseases (RD) in terms of prevention, recognition, diagnosis, treatment, care and research along key RD specificities, such as great heterogeneity, a limited number of patients, scarcity of relevant knowledge and expertise as well as enormous costs for patient care is a challenging task for healthcare providers and authorities that makes a supranational approach particularly feasible. The European Union has acknowledged RD matters by several initiatives, including efforts to implement national centres of expertise and European reference networks as well as a cross-border referral mechanism to foster access to expert services and to boost dissemination of clinical expertise and research activities. Exemplified by the EB House Austria, a centre of expertise for epidermolysis bullosa cross-linked with international reference partner institutions, this strategy proves its potential to be translated into optimized patient care and to meet the major medical, scientific, social and health-economic impact of RD.

21 May 2024 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
GSGudrun Salamon
Gudrun Salamon
UFUrsula Field-Werners
Ursula Field-Werners
SSSophie Strobl
Sophie Strobl
VHVinzenz Hübl
Vinzenz Hübl
ADAnja Diem
Anja Diem
Background: With approximately 500 people affected in Austria, epidermolysis bullosa (EB) is a rare genetic skin disease reducing the quality of life of those affected and their relatives. The intensive efforts of the patient organisation DEBRA Austria during the last decades have led to a unique situation of those affected and their relatives, with increased support and broader knowledge about the disease in the general population. The aim of the study is to evaluate the current situation of patients and their relatives living in Austria, with a focus on burdens and helpful practices. Results: The mixed-methods study consisted of two parts: a qualitative interview study to identify psychosocial aspects of EB in those affected and their relatives, and a subsequent online survey to further assess those aspects in a larger sample, resulting in a total of n=78 Austrian participants. The impact of EB on the quality of life of EB patients and their relatives in Austria is related to the current health status, psychological burden, mobility, visibility, financial situation as well as job prospects. Personal and social resources and external support have a significant influence on the individual situation. Conclusions: The outcome is mapped to concrete implications regarding targeted support for EB patients and their relatives on an individual level and their needs in regard to the Austrian health care system.

14 April 2005 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Closed access
PDF file
ESElke Sadler
Elke Sadler
MLMartin Laimer
Martin Laimer
ADAnja Diem
Anja Diem
AKAlfred Klausegger
Alfred Klausegger
GPGabriele Pohla‐Gubo
Gabriele Pohla‐Gubo
HHHelmut Hintner
Helmut Hintner

1 November 2018 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
MAMichael Ablinger
Michael Ablinger
Thomas FelderThomas Felder
Thomas Felder
MWMonika Wimmer
Monika Wimmer
RZRoland Zauner
Roland Zauner
PHPeter Hofbauer
Peter Hofbauer
VWVerena Wally
Verena Wally
Generalized severe epidermolysis bullosa simplex (EBS-gen sev) is caused by mutations within either the KRT5 or KRT14 gene, phenotypically resulting in blistering and wounding of the skin and mucous membranes after minor mechanical friction. In a clinical phase 2/3 trial, diacerein has recently been shown to significantly reduce blister numbers upon topical application. In this study we addressed basic pharmacokinetic parameters of locally applied diacerein in vitro and in vivo. Ex vivo experiments using a Franz diffusion cell confirmed the uptake and bio-transformation of diacerein to rhein in a porcine skin model. Rhein, the active metabolite of diacerein, was also detected in both urine and serum samples of two EBS-gen sev patients who topically applied a 1% diacerein ointment over a period of 4 weeks. The accumulated systemic levels of rhein in EBS-gen sev patients were lower than reported levels after oral application. These preliminary findings point towards the uptake and prolonged persistance of diacerein / rhein within the intended target organ - the skin. Further, they imply an acceptable safety profile at the systemic level. DRKS. DRKS00005412 . Registered 6 November 2013.